Характеристика показників серцево-судинного ремоделювання та плазмового рівня остеопонтину під впливом терапії кандесартаном у пацієнтів на додіалізних стадіях хронічної хвороби нирок

Philippe Van De Borne, Guidelines for the management of arterial hypertension Acta Cardiologica. ,vol. 69, pp. 53- 54 ,(2014) , 10.2143/AC.69.1.3011345

Donald W. Cockcroft, Henry Gault, Prediction of Creatinine Clearance from Serum Creatinine Nephron. ,vol. 16, pp. 31- 41 ,(1976) , 10.1159/000180580

Johan M. Lorenzen, Henrike Neunhöffer, Sascha David, Jan T. Kielstein, Hermann Haller, Danilo Fliser, Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial. Atherosclerosis. ,vol. 209, pp. 184- 188 ,(2010) , 10.1016/J.ATHEROSCLEROSIS.2009.09.009

Min Wu, Rining Tang, Linli Lv, Kunling Ma, Xiaoliang Zhang, Bicheng Liu, Parathyroid hormone induces endothelial-to-mesenchymal transition in human aortic endothelial cells International Journal of Cardiology. ,vol. 152, pp. S65- ,(2011) , 10.1016/J.IJCARD.2011.08.682

Hans Lithell, Lennart Hansson, Ingmar Skoog, Dag Elmfeldt, Albert Hofman, Bertil Olofsson, Peter Trenkwalder, Alberto Zanchetti, SCOPE Study Group, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension. ,vol. 21, pp. 875- 886 ,(2003) , 10.1097/00004872-200305000-00011

Juan B. Grau, Paolo Poggio, Rachana Sainger, William J. Vernick, William F. Seefried, Emanuela Branchetti, Benjamin C. Field, Joseph E. Bavaria, Michael A. Acker, Giovanni Ferrari, Analysis of Osteopontin Levels for the Identification of Asymptomatic Patients With Calcific Aortic Valve Disease The Annals of Thoracic Surgery. ,vol. 93, pp. 79- 86 ,(2012) , 10.1016/J.ATHORACSUR.2011.08.036

Sachiko Sakurabayashi-Kitade, Yoshikazu Aoka, Hirotaka Nagashima, Hiroshi Kasanuki, Nobuhisa Hagiwara, Masatoshi Kawana, Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice. Atherosclerosis. ,vol. 206, pp. 54- 60 ,(2009) , 10.1016/J.ATHEROSCLEROSIS.2009.01.039

Hiroyuki Nakayama, Hiromi Nagai, Kyotaka Matsumoto, Ryosuke Oguro, Ken Sugimoto, Kei Kamide, Mitsuru Ohishi, Tomohiro Katsuya, Hiroshi Okamoto, Makiko Maeda, Kazuo Komamura, Junichi Azuma, Hiromi Rakugi, Yasushi Fujio, Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese population. Hypertension Research. ,vol. 34, pp. 1141- 1146 ,(2011) , 10.1038/HR.2011.102

M Kurata, T Okura, J Irita, D Enomoto, T Nagao, M Jotoku, K Miyoshi, V R Desilva, J Higaki, Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. Journal of Human Hypertension. ,vol. 25, pp. 334- 339 ,(2011) , 10.1038/JHH.2010.73

Richard B. Devereux, Daniel R. Alonso, Elizabeth M. Lutas, Geoffrey J. Gottlieb, Emilio Campo, Irene Sachs, Nathaniel Reichek, Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings American Journal of Cardiology. ,vol. 57, pp. 450- 458 ,(1986) , 10.1016/0002-9149(86)90771-X